Free Trial
NASDAQ:RNAC

Cartesian Therapeutics 8/8/2024 Earnings Report

Cartesian Therapeutics logo
$10.44 +0.54 (+5.45%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$10.42 -0.03 (-0.24%)
As of 05:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cartesian Therapeutics EPS Results

Actual EPS
$0.54
Consensus EPS
-$0.81
Beat/Miss
Beat by +$1.35
One Year Ago EPS
N/A

Cartesian Therapeutics Revenue Results

Actual Revenue
$33.45 million
Expected Revenue
$6.00 million
Beat/Miss
Beat by +$27.45 million
YoY Revenue Growth
N/A

Cartesian Therapeutics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Cartesian Therapeutics Earnings Headlines

Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More Cartesian Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cartesian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cartesian Therapeutics and other key companies, straight to your email.

About Cartesian Therapeutics

Cartesian Therapeutics (NASDAQ:RNAC), a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

View Cartesian Therapeutics Profile

More Earnings Resources from MarketBeat